题名

The impact of phyto- and endo-cannabinoids on central nervous system diseases: A review

DOI

10.1016/j.jtcme.2022.10.004

作者

Shan-Shan Zhang；Niu-Niu Zhang；Tian-Tian Guo；Lee-Yan Sheen；Chi-Tang Ho；Nai-Sheng Bai

关键词

Cannabinoids ； Chemical structures ； Endocannabinoid system ； CNS diseases

期刊名称

Journal of Traditional and Complementary Medicine

卷期/出版年月

13卷1期（2023 / 01 / 01）

页次

30 - 38

内容语文

英文
中文摘要

Background and aim: Cannabis sativa L. is a medicinal plant with a long history. Phyto-cannabinoids are a class of compounds from C. sativa L. with varieties of structures. Endocannabinoids exist in the human body. This article provides an overview of natural cannabinoids (phyto-cannabinoids and endocannabinoids) with an emphasis on their pharmacology activities. Experimental procedure: The keywords "Cannabis sativa L", "cannabinoids", and "central nervous system (CNS) diseases" were used for searching and collecting pieces of literature from PubMed, ScienceDirect, Web of Science, and Google Scholar. The data were extracted and analyzed to explore the effects of cannabinoids on CNS diseases. Result and conclusion: In this paper, schematic diagrams are used to intuitively show the phytocannabinoids skeletons' mutual conversion and pharmacological activities, with special emphasis on their relevant pharmacological activities on central nervous system (CNS) diseases. It was found that the endocannabinoid system and microglia play a crucial role in the treatment of CNS diseases. In the past few years, pharmacological studies focused on Δ^9-THC, CBD, and the endocannabinoids system. It is expected to encourage new studies on a more deep exploration of other types of cannabinoids and the mechanism of their pharmacological activities in the future.
主题分类 醫藥衛生 > 中醫藥學
参考文献
  1. Ahmed, SA,Ross, SA,Slade, D,Radwan, MM,Zulfiqar, F,ElSohly, MA(2008).Cannabinoid ester constituents from high-potency Cannabis sativa.J Nat Prod,71(4),536-542.
  2. Ashton, CH,Moore, PB(2011).Endocannabinoid system dysfunction in mood and related disorders.Acta Psychiatr Scand,124(4),250-261.
  3. Aso, E,Sánchez-Pla, A,Vegas-Lozano, E,Maldonado, R,Ferrer, I(2015).Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.J Alzheim Dis,43(3),977-991.
  4. Augustin, SM,Lovinger, DM(2022).Synaptic changes induced by cannabinoid drugs and cannabis use disorder.Neurobiol Dis,167,105670.
  5. Aymerich, MS,Aso, E,Abellanas, MA(2018).Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.Biochem Pharmacol,157,67-84.
  6. Babson, KA,Sottile, J,Morabito, D(2017).Cannabis, cannabinoids, and sleep: a review of the literature.Curr Psychiatr Rep,19(4),23.
  7. Bauer, R,Woelkart, K,Salo-Ahen, O(2008).CB receptor ligands from plants.Curr Top Med Chem,8(3),173-186.
  8. Baul, HS,Manikandan, C,Sen, D(2019).Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.Brain Res Bull,146,244-252.
  9. Bellesi, M,De Vivo, L,Chini, M,Gilli, F,Tononi, G,Cirelli, C(2017).Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex.J Neurosci,37(21),5263-5273.
  10. Benito, C,Romero, JP,Tolon, RM(2007).Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.J Neurosci,27(9),2396-2402.
  11. Bobrich, M,Schwarz, R,Ramer, R,Borchert, P,Hinz, B(2020).A simple LC-MS/MS method for the simultaneous quantification of endocannabinoids in biological samples.J Chromatogr B,1161,122371.
  12. Choi, S,Huang, BC,Gamaldo, CE(2020).Therapeutic uses of cannabis on sleep disorders and related conditions.J Clin Neurophysiol,37(1),39-49.
  13. Crotti, A,Glass, CK(2015).The choreography of neuroinflammation in Huntington's disease.Trends Immunol,36(6),364-373.
  14. Da Rovare, VP,Magalhães, GPA,Jardini, GDA(2017).Cannabinoids for spasticity due to multiple sclerosis or paraplegia: a systematic review and meta-analysis of randomized clinical trials.Compl Ther Med,34,170-185.
  15. Di Marzo, V,Bifulco, M,De Petrocellis, L(2004).The endocannabinoid system and its therapeutic exploitation.Nat Rev Drug Discov,3(9),771-784.
  16. Dowie, MJ,Howard, ML,Nicholson, LFB,Faull, RLM,Hannan, AJ,Glass, M(2010).Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.Neuroscience,170(1),324-336.
  17. Duffy, SS,Hayes, JP,Fiore, NT,Moalem-Taylor, G(2021).The cannabinoid system and microglia in health and disease.Neuropharmacology,190,108555.
  18. Fernández-Ruiz, J(2009).The endocannabinoid system as a target for the treatment of motor dysfunction.Br J Pharmacol,156(7),1029-1040.
  19. Fezza, F,Marrone, MC,Avvisati, R(2014).Distinct modulation of the endo-cannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting.Mol Cell Neurosci,62,1-9.
  20. Gaoni, Y,Mechoulam, R(1964).Isolation, structure, and partial synthesis of an active constituent of Hashish.J Am Chem Soc,86(8),1646-1647.
  21. Garofano, F,Schmidt-Wolf, IGH(2020).High expression of cannabinoid receptor 2 on cytokine-induced killer cells and multiple myeloma cells.Int J Mol Sci,21(11),3800.
  22. Gaston, TE,Friedman, D(2017).Pharmacology of cannabinoids in the treatment of epilepsy.Epilepsy Behav,70,313-318.
  23. Gates, PJ,Albertella, L,Copeland, J(2014).The effects of cannabinoid administration on sleep: a systematic review of human studies.Sleep Med Rev,18(6),477-487.
  24. Gómez-Gálvez, Y,Palomo-Garo, C,Fernández-Ruiz, J,García, C(2016).Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease.Prog Neuro Psychopharmacol Biol Psychiatr,64,200-208.
  25. Gowran, A,Noonan, J,Campbell, VA(2011).The multiplicity of action of cannabinoids: implications for treating neurodegeneration.CNS Neurosci Ther,17(6),637-644.
  26. Hanuš, LO,Meyer, SM,Muñoz, E,Taglialatela-Scafati, O,Appendino, G(2016).Phyto-cannabinoids: A Unified Critical Inventory.Natural Product Reports,33
  27. Hill, MN,Gorzalka, BB(2005).Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?.Behav Pharmacol,16(5-6),333-352.
  28. Hill, MN,Miller, GE,Carrier, EJ,Gorzalka, BB,Hillard, CJ(2009).Circulating endocanna-binoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress.Psychoneuroendocrinology,34(8),1257-1262.
  29. Hill, MN,Miller, GE,Ho, WSV,Gorzalka, BB,Hillard, CJ(2008).Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report.Pharmacopsychiatry,41(2),48-53.
  30. Holgado, MA,Martín-Banderas, L,Álvarez-Fuentes, J,Fernández-Arévalo, M(2017).Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases.J Drug Deliv Sci Technol,42,84-93.
  31. Husni, AS,McCurdy, CR,Radwan, MM(2014).Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2.Med Chem Res,23(9),4295-4300.
  32. Ibarra-Lecue, I,Pilar-Cuéllar, F,Muguruza, C(2018).The endocannabinoid system in mental disorders: evidence from human brain studies.Biochem Pharmacol,157,97-107.
  33. Jacobs, JA,Sehgal, A(2020).Anandamide metabolites protect against seizures through the TRP channel water witch in Drosophila melanogaster.Cell Rep,31(9),107710.
  34. Javid, FA,Phillips, RM,Afshinjavid, S,Verde, R,Ligresti, A(2016).Cannabinoid pharmacology in cancer research: a new hope for cancer patients?.Eur J Pharmacol,775,1-14.
  35. Köfalvi, A,Rodrigues, RJ,Ledent, C(2005).Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.J Neurosci,25(11),2874-2884.
  36. Lastres-Becker, I,Molina-Holgado, F,Ramos, JA,Mechoulam, R,Fernández-Ruiz, J(2005).Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.Neurobiol Dis,19(1-2),96-107.
  37. Liu, R,Pan, M-X,Tang, J-C(2017).Role of neuroinflammation in ischemic stroke.Neuroimmunol Neuroinflammation,4(8),158-166.
  38. Long, JZ,Li, W,Booker, L(2009).Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.Nat Chem Biol,5(1),37-44.
  39. Lustenberger, S,Boczkaj, G,Castro-Muñoz, R(2022).Cannabinoids: challenges, opportunities and current techniques towards its extraction and purification for edibles.Food Biosci,49,101835.
  40. Manchanda, S,Singh, H,Kaur, T,Kaur, G(2018).Low-grade neuroinflammation due to chronic sleep deprivation results in anxiety and learning and memory impairments.Mol Cell Biochem,449(1-2),63-72.
  41. Mathers, DC,Ghodse, AH(1992).Cannabis and psychotic illness.Br J Psychiatry,161,648-653.
  42. Maurya, N,Velmurugan, BK(2018).Therapeutic applications of cannabinoids.Chem Biol Interact,293,77-88.
  43. McPartland, JM,Duncan, M,Di Marzo, V,Pertwee, RG(2015).Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.Br J Pharmacol,172(3),737-753.
  44. Mecha, M,Feliú, A,Carrillo-Salinas, FJ(2015).Endocannabinoids drive the acquisition of an alternative phenotype in microglia.Brain Behav Immun,49,233-245.
  45. Mechoulam, R,Parker, LA(2013).The endocannabinoid system and the brain.Annu Rev Psychol,64,21-47.
  46. Mikita, J,Dubourdieu-Cassagno, Nadège,Deloire, MS(2011).Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration.Mult Scler J,17(1),2-15.
  47. Morales, P,Jagerovic, N.(2016).Advances towards the discovery of GPR55 ligands.Curr Med Chem,23(20),2087-2100.
  48. Moreno, M,Bannerman, P,Ma, J(2014).Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in Mice with MOG peptide EAE.J Neurosci,34(24),8175-8185.
  49. Mullington, JM,Simpson, NS,Meier-Ewert, HK,Haack, M(2010).Sleep loss and inflammation.Best Pract Res Clin Endocrinol Metabol,24(5),775-784.
  50. Navarro, G,Borroto-Escuela, D,Angelats, E(2018).Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia.Brain Behav Immun,67,139-151.
  51. Nogueiras, R,Veyrat-Durebex, C,Suchanek, PM(2008).Peripheral, but Not Central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.Diabetes,57(11),2977-2991.
  52. Palazuelos, J,Aguado, T,Pazos, MR(2009).Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.Brain,132(11),3152-3164.
  53. Pascual, D,García, MM,Goicoechea, C(2018).Chronic pain and cannabinoids. Great expectations or a christmas carol.Biochem Pharmacol,157,33-42.
  54. Rodziewicz, P,Loroch, S,Marczak, Ł,Sickmann, A,Kayser, O(2019).Cannabinoid synthases and osmoprotective metabolites accumulate in the exudates of Cannabis sativa L. glandular trichomes.Plant Sci,284,108-116.
  55. Rosenberg, EC,Patra, PH,Whalley, BJ(2017).Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.Epilepsy Behav,70,319-327.
  56. Semple, DM,McIntosh, AM,Lawrie, SM(2005).Cannabis as a risk factor for psychosis: systematic review.J Psychopharmacol,19(2),187-194.
  57. Shahbazi, F,Grandi, V,Banerjee, A,Trant, JF(2020).Cannabinoids and cannabinoid receptors: the story so far.iScience,23(7),101301.
  58. Shokri-Kojori, E,Wang, GJ,Wiers, CE(2018).b-Amyloid accumulation in the human brain after one night of sleep deprivation.Proc Natl Acad Sci U S A,115(17),4483-4488.
  59. Sieradzan, KA,Fox, SH,Hill, M,Dick, JPR,Crossman, AR,Brotchie, JM(2001).Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.Neurology,57(11),2108-2111.
  60. Slevin, M,Matou, S,Zeinolabediny, Y(2015).Monomeric C-reactive protein - a key molecule driving development of Alzheimer's disease associated with brain ischaemia?.Sci Rep,5,1-21.
  61. Solas, M,Francis, PT,Franco, R,Ramirez, MJ(2013).CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.Neurobiol Aging,34(3),805-808.
  62. Suraev, AS,Marshall, NS,Vandrey, R(2020).Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies.Sleep Med Rev,53,101339.
  63. Sveinbjornsdottir, S(2016).The clinical symptoms of Parkinson's disease.J Neurochem,139,318-324.
  64. Szkudlarek, HJ,Rodríguez-Ruiz, M,Hudson, R(2021).THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways.Prog Neuro Psychopharmacol Biol Psychiatr,104,110029.
  65. Van Den Elsen, GAH,Tobben, L,Ahmed, AIA(2017).Effects of tetrahydrocan-nabinol on balance and gait in patients with dementia: a randomized controlled crossover trial.J Psychopharmacol,31(2),184-191.
  66. Welcome, MO(2020).Neuroinflammation in CNS diseases: molecular mechanisms and the therapeutic potential of plant derived bioactive molecules.PharmaNutrition,11,100176.
  67. Yao, I,Stein, ES,Maggio, N(2019).Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy.Pharmacol Ther,202,32-39.
  68. Yiangou, Y,Facer, P,Durrenberger, P(2006).COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.BMC Neurol,6,1-14.
  69. Zalesky, A,Solowij, N,Yücel, M(2012).Effect of long-term cannabis use on axonal fibre connectivity.Brain,135(7),2245-2255.
  70. Zhu, B,Dong, Y,Xu, Z(2012).Sleep disturbance induces neuroinflammation and impairment of learning and memory.Neurobiol Dis,48(3),348-355.
print cancel